Apollomics, Inc. Doses First Patient in A Phase I Clinical Trial of APL-102
Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced […]